{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-447608","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-11-04T22:10:44+00:00","discovered_at":"2026-11-04T22:12:00.359007+00:00","generated_at":"2026-11-04T22:12:08.527096+00:00","sec_items":["1.01","3.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones","bullets":["Evommune pays Hinova $20M cash plus pre-funded warrants for 1,262,413 shares ($10M) at $0.001 exercise, for $30M total upfront.","Milestones up to ~$1.1B: $150M development/regulatory and $920M commercial, plus tiered royalties from mid-single-digit to low-double-digit on ex-Greater China net sales.","Rights cover worldwide excluding Greater China, which Hinova retains; Phase 1 expected to begin imminently, with a Phase 2 rheumatoid arthritis trial planned for 2027.","$30M private placement: 4,966,889 shares at $6.04 to investors including Adage, Balyasny, OrbiMed and Squadron; closing expected on or about November 6, 2026.","Pro forma cash, cash equivalents and investments estimated at ~$292.3M after closing, sufficient to fund operations into the second half of 2029."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-447608","json":"https://secwatch.observer/filing/0001193125-26-447608.json","markdown":"https://secwatch.observer/filing/0001193125-26-447608.md","text":"https://secwatch.observer/filing/0001193125-26-447608.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/0001193125-26-447608-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526447608/evmn-20261104.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-04T22:12:08.527096+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}